INSUGEN now available in M’sia
BANDAR UTAMA: The Malaysian diabetic community’s access to a bigger portfolio of safe, affordable and quality treatment options received a boost with the introduction of CCM-Biocon’s recombinant human insulin; INSUGEN® in Malaysia.
INSUGEN® is indigenously developed by Biocon and will be exclusively distributed and marketed by CCM PharmaceuticalsSdnBhd,awholly owned subsidiary of Chemical Company of Malaysia Berhad (CCM) for the Malaysian market. This is the first generic insulin to be introduced in the country which will enable greater access to quality biopharmaceuticals for a larger diabetic patient pool.
Biocon is India’s largest biopharmaceutical company with a wide portfolio of rh- insulins and analogs. It is the world’s fourth largest insulins producer and is committed to making diabetic care affordable and convenient for patients worldwide.
Generic insulin is developed using similar genetic contents and are designed to have the same mechanism of action in terms of safety and efficacy as the original biopharmaceutical products.
The development of generic insulin is a complex process that involves extensive research and development including clinical trials. It requires large scale investments for development and high end manufacturing capabilities to ensure patients have access to a high quality biopharmaceutical product.
With an investment of over US$160 million, the largest foreign investment in Malaysia’s healthcare sector, Biocon has been recognised as an Entry Point Project (EPP) by the government and is expected to play a major role in the government’s economic transformation programme.
First introduced by Biocon in 2004, INSUGEN® is indigenously developed by Biocon using a proprietary fermentation technology. The company has been the fastest growing insulins company in India since the launch of INSUGEN®, the leading domestic rh-insulin brand. Biocon is credited for providing rhinsulin to over 50 countries across the world, thus making diabetes management easy and affordable for a large pool of patients.
INSUPen® is a first-in-class reusable delivery device designed to be easy to use, providing accurate and reliable dosing. It can be used with INSUGEN®, thus maximizing patient convenience. This German-technology pen is available in two variants.
The first is a metallic-bodied pen which is available in three colours for clear insulin differentiation to reduce administration errors. The second is a plastic-bodied pen which is lightweight and more economical, thus enhancing access to this quality device for a growing pool of diabetics in the country.
INSUGEN® and INSUPen® are recommended for patients with type 1 and type 2 diabetes and have been approved by National Pharmaceutical Control Bureau (NPCB).